Sun Pharmaceutical Industries Ltd

The key equity benchmarks witnessed strong gains in mid-morning trade supported by positive global cues after softer-than-expected U.S. inflation data eased concerns over further interest rate hikes by the Federal Reserve. Improved global risk sentiment and buying across frontline stocks lifted the domestic indices, with the Nifty trading above the 24,150 mark. Investors will continue to monitor developments in the US-Iran conflict, movements in crude oil prices, the ongoing Q1 earnings season, corporate business updates, and the progress of the southwest monsoon for further cues on market direction. Private bank shares recovered after falling in the previous trading session. At 11:25 IST, the barometer index, the S&P BSE Sensex advanced 479.41 points or 0.64% to 77,545.01. The Nifty 50 index added 133.95 points or 0.56% to 24,186. In the broader market, the BSE 150 MidCap Index jumped 0.62% and the BSE 250 SmallCap Index climbed 0.97%. The market breadth was strong. On the BSE, 2,495 shares rose and 1,346 shares fell. A total of 219 shares were unchanged. IPO Update: The initial public offer (IPO) of Alphine Texoworld received bids for 55.32 lakh shares as against 1.20 crore shares on offer, as per NSE data as of 11:21 hours on Wednesday (15 July 2026). The issue was subscribed 0.46 times. The issue opened for bidding on Tuesday (14 July 2026) and it will close on Thursday (16 July 2026). The price band of the IPO is fixed between Rs 100 to Rs 105 per share. The minimum order quantity is 142 equity shares. SBI Funds Management IPO received bids for 2.39 crore shares as against 14.51 crore shares on offer, according to stock exchange data at 11:21 IST on Wednesday (15 July 2026). The issue was subscribed 1.17 times. The issue opened for bidding on 14 July 2026 and it will close on 16 July 2026. The price band of the IPO is fixed between Rs 545 and 574 per share. An investor can bid for a minimum of 26 equity shares and multiples thereof. Buzzing Index: The Nifty Private Bank index advanced 1.01% to 28,198. The index declined 0.85% in the past trading session. Bandhan Bank (up 5.69%), IndusInd Bank (up 2.47%), Axis Bank (up 1.39%), ICICI Bank (up 1.13%) and HDFC Bank (up 0.93%), IDFC First Bank (up 0.71%), RBL Bank (up 0.57%), Kotak Mahindra Bank (up 0.51%), Yes Bank (up 0.51%) and Federal Bank (up 0.12%) advanced. Stocks in Spotlight: Sun Pharmaceutical Industries rose 0.89%. The company announced that it has received approval from the South African Health Products Regulatory Authority (SAHPRA) to manufacture and market a generic version of semaglutide injection in South Africa. Belrise Industries rose 2.45% after the company announced the launch of its qualified institutional placement (QIP) issue and fixed the floor price at Rs 230.79 per equity share. The floor price of Rs 230.79 per share is at a discount of 0.65% to the scrip's previous closing price of Rs 232.30 on the BSE. Global Markets: Asian markets advanced on Wednesday after a surprise slowdown in U.S. inflation scaled back market expectations for interest rate hikes, while oil took a breather as the U.S. scrapped a plan to levy shipping through the Strait of Hormuz. U.S. President ⁠Donald Trump reimposed a naval blockade of Iranian ports on Tuesday and threatened to attack power plants and bridges next week unless Iran resumes negotiations to end their conflict, though he scrapped a plan for a 20% fee on ⁠shipping through Hormuz. Meanwhile, China's economy in the second quarter expanded at its weakest pace since the fourth quarter of 2022. These figures reinforce calls for policy stimulus as an accelerating slide in investments deepened the strain on growth, while consumption stayed subdued. Gross domestic product growth came in at 4.3% in the April to June period, data from the National Statistics Bureau showed Wednesday, missing widely reported forecast for 4.5% growth, and slowing from 5% in the first quarter. That second-quarter growth came below Beijing's full-year growth target range of 4.5% to 5%, the least ambitious goal in decades, amid tensions with trade partners, including the U.S. and the European Union, and sluggish domestic demand. The S&P 500 and the Nasdaq advanced on Tuesday as solid big bank results and a cooler-than-expected inflation report boosted risk appetite amid rising Middle East tensions. The U.S. headline consumer price index fell 0.4% in June, its first decline since the COVID-19 pandemic, while annualised core inflation of 2.6% compared with widely reported expectations for 2.8%. The Labor Department's Consumer Price Index showed inflation cooled more than analysts expected in June, largely due to abating energy price pressures amid last month's signs of progress in U.S.-Iran peace negotiations.Powered by Capital Market - Live

The drug will be used for the treatment of adults with inadequately controlled type 2 diabetes mellitus as an adjunct to diet and exercise. Sun Pharma plans to launch the product in the market in the coming days. It will be available as a pre-filled, multi-dose injectable pen in two strengths'2 mg/1.5 mL and 4 mg/3 mL'allowing flexible, once-weekly dosing. 'South Africa is the second market after India where Sun Pharma has received approval for generic semaglutide. This reflects our ability to develop complex generic medicines that meet the stringent quality standards across different markets. We remain committed to improving access to generics and making evidence-based treatment options available to patients and healthcare professionals, said Aalok Shanghvi, chief operating officer, Sun Pharma. The company said that South Africa faces a growing burden of type 2 diabetes, driven in part by rapid urbanization and changing lifestyles. This rising prevalence places significant pressure on patients and the healthcare system. Improving access to effective therapies is therefore an important component of addressing this national health challenge. Sun Pharmaceutical Industries is engaged in the business of manufacturing, developing and marketing a wide range of branded and generic formulations and active pharmaceutical ingredients (APIs). The company and its subsidiaries has various manufacturing facilities spread across the world, with trading and other incidental and related activities extending to the global market. It is the largest pharmaceutical company in India. The company had reported a 26.24% rise in consolidated net profit to Rs 2,714.03 crore in Q4 FY26 as against Rs 2,149.88 crore posted in the same period year ago. Total revenue from operations increased 12.75% YoY to Rs 14,611.79 crore in the quarter ended 31 March 2026. The scrip rose 0.46% to currently trade at Rs 1,949 on the BSE. Powered by Capital Market - Live

Sun Pharmaceutical Industries has received approval from the South African Health Products Regulatory Authority (SAHPRA) to manufacture and market a generic version of semaglutide injection in South Africa for the treatment of adults with inadequately controlled type 2 diabetes mellitus as an adjunct to diet and exercise. Sun Pharma plans to launch the product in the market in the coming days. It will be available as a pre-filled, multi-dose injectable pen in two strengths (2 mg/1.5 mL and 4 mg/3 mL) that allow flexible, once-weekly dosing. 'South Africa is the second market after India where Sun Pharma has received approval for generic semaglutide. This reflects our ability to develop complex generic medicines that meet the stringent quality standards across different markets. We remain committed to improving access to generics and making evidence-based treatment options available to patients and healthcare professionals, said Aalok Shanghvi, Chief Operating Officer, Sun Pharma.

Sun Pharmaceuticals Industries will hold a meeting of the Board of Directors of the Company on 31 July 2026.

Sun Pharmaceutical Industries Ltd rose for a fifth straight session today. The stock is quoting at Rs 1914.2, up 0.07% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is up around 0.17% on the day, quoting at 24472.4. The Sensex is at 78420.16, up 0.17%. Sun Pharmaceutical Industries Ltd has added around 7.01% in last one month. Meanwhile, Nifty Pharma index of which Sun Pharmaceutical Industries Ltd is a constituent, has added around 6.88% in last one month and is currently quoting at 25866.25, down 0.22% on the day. The volume in the stock stood at 10.77 lakh shares today, compared to the daily average of 19.54 lakh shares in last one month. The benchmark July futures contract for the stock is quoting at Rs 1917.1, down 0.05% on the day. Sun Pharmaceutical Industries Ltd is up 14.45% in last one year as compared to a 4.11% fall in NIFTY and a 16.43% fall in the Nifty Pharma index.The PE of the stock is 152.92 based on TTM earnings ending March 26.Powered by Capital Market - Live

Sun Pharmaceutical Industries Ltd is up for a third straight session in a row. The stock is quoting at Rs 1911.1, up 2.14% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is up around 0.74% on the day, quoting at 24354.25. The Sensex is at 78056.84, up 0.72%. Sun Pharmaceutical Industries Ltd has risen around 7.36% in last one month. Meanwhile, Nifty Pharma index of which Sun Pharmaceutical Industries Ltd is a constituent, has risen around 6.77% in last one month and is currently quoting at 25308.9, up 2% on the day. The volume in the stock stood at 15.41 lakh shares today, compared to the daily average of 20.27 lakh shares in last one month. The benchmark July futures contract for the stock is quoting at Rs 1915.8, up 2.17% on the day. Sun Pharmaceutical Industries Ltd is up 14.01% in last one year as compared to a 4.35% drop in NIFTY and a 15.33% drop in the Nifty Pharma index.The PE of the stock is 149.6 based on TTM earnings ending March 26.Powered by Capital Market - Live

Sun Pharmaceutical Industries Ltd gained for a fifth straight session today. The stock is quoting at Rs 1885, up 1.19% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is down around 0.64% on the day, quoting at 23948.45. The Sensex is at 76610.4, down 0.63%. Sun Pharmaceutical Industries Ltd has risen around 2.41% in last one month. Meanwhile, Nifty Pharma index of which Sun Pharmaceutical Industries Ltd is a constituent, has risen around 1.62% in last one month and is currently quoting at 24762.9, up 1.26% on the day. The volume in the stock stood at 16.35 lakh shares today, compared to the daily average of 26.88 lakh shares in last one month. The benchmark June futures contract for the stock is quoting at Rs 1883.8, up 1.11% on the day. Sun Pharmaceutical Industries Ltd is up 13.44% in last one year as compared to a 4.38% drop in NIFTY and a 15.7% drop in the Nifty Pharma index.The PE of the stock is 148.96 based on TTM earnings ending March 26.Powered by Capital Market - Live

Innovcare Lifesciences is engaged in the business of marketing, distribution and sale of pharmaceutical drugs, nutraceutical and cosmeceutical products. The revenue from operations for FY 2025-26 was Rs 94.06 crore. Sun Pharma stated that this acquisition is being done to strengthen product portfolio of the company. The company expects to complete this transaction before 31 July 2026. Sun Pharmaceutical Industries is engaged in the business of manufacturing, developing and marketing a wide range of branded and generic formulations and active pharmaceutical ingredients (APIs). The company and its subsidiaries has various manufacturing facilities spread across the world, with trading and other incidental and related activities extending to global market. It is the largest pharmaceutical company in India. The company had reported 26.24% rise in consolidated net profit to Rs 2,714.03 crore in Q4 FY26 as against Rs 2,149.88 crore posted in the same period year ago. Total revenue from operations increased 12.75% YoY to Rs 14,611.79 crore in the quarter ended 31 March 2026. The scrip advanced 0.85% to currently trade at Rs 1852.70 on the BSE. Powered by Capital Market - Live

Securities in F&O Ban: Shares of Kaynes Technology India are banned from F&O trading on 22 June 2026. Stocks to Watch: Sun Pharmaceuticals Industries has entered into an agreement to acquire 100% stake in Innovcare Lifesciences, based in Mumbai and engaged in the business of marketing, distribution and sale of pharmaceutical drugs, nutraceutical and cosmeceutical products. The total consideration of the transaction is valued at Rs 271.2 crore. Garden Reach Shipbuilders & Engineers (GRSE) has been granted Navratna status by the Department of Public Enterprises (DPE) under the Ministry of Finance. The company said the recognition reflects its strong financial performance, operational efficiency and contribution to national security. GE Power India announced a series of senior leadership changes, including the appointment of Rahul Rojal as Chief Financial Officer (CFO), as the company strengthens its management team amid ongoing business and project execution initiatives. Goodluck India announced that its subsidiary, Goodluck Defence and Aerospace, has secured an order worth approximately Rs 255 crore for the supply of 155 mm long-range empty shells in ready-to-fill condition. Zaggle Prepaid Ocean Services (Zaggle) announced that it has entered into an agreement with Punjab National Bank (PNB) to act as a co-branding partner for a retail credit card product. Under the agreement, Zaggle will leverage its existing corporate customer base to drive acquisition, marketing and promotion of the co-branded retail credit card. The partnership is aimed at expanding the reach of the co-branded card offering. Texmaco Rail & Engineering has received a letter of intent (LoI) worth Rs 253.28 crore from JSW (South) Rail Logistics for the manufacture and supply of BFNSM1 rakes along with BVCM wagons. The domestic order is scheduled to be executed within 13.5 months from the effective date or commencement of work.Powered by Capital Market - Live

Sun Pharmaceuticals Industries announced that the 34th Annual General Meeting(AGM) of the company will be held on 31 July 2026.